InvestorsHub Logo
Followers 468
Posts 26926
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 32

Wednesday, 09/26/2012 8:23:00 AM

Wednesday, September 26, 2012 8:23:00 AM

Post# of 62
4:04AM Theravance and GlaxoSmithKline (GSK) receive FDA acceptance of FF/VI New Drug Application submission in the US for COPD (THRX) 25.76 : GlaxoSmithKline plc (GSK) and Theravance (THRX) announce that the New Drug Application for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" for patients with chronic obstructive pulmonary disease, has been accepted by the FDA indicating that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act goal date has also been confirmed as 12th May 2013. GSK also submitted a Japanese New Drug Application for FF/VI for patients with COPD and asthma on 25th September 2012.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent THRX News